Pulmonology最新文献_第8页

Impact of treating obesity hypoventilation syndrome on body mass index. 治疗肥胖低通气综合征对体重指数的影响。

IF 10.4 2区医学

Pulmonology Pub Date : 2025-12-31 Epub Date: 2024-10-24 DOI: 10.1016/j.pulmoe.2023.09.004

R G S Andrade, J F Masa, J-C Borel, L F Drager, P R Genta, B Mokhlesi, G Lorenzi-Filho

{"title":"Impact of treating obesity hypoventilation syndrome on body mass index.","authors":"R G S Andrade, J F Masa, J-C Borel, L F Drager, P R Genta, B Mokhlesi, G Lorenzi-Filho","doi":"10.1016/j.pulmoe.2023.09.004","DOIUrl":"10.1016/j.pulmoe.2023.09.004","url":null,"abstract":"<p><strong>Study objectives: </strong>To evaluate the impact of positive airway pressure (PAP) therapy on body mass index (BMI) in patients with obesity hypoventilation syndrome (OHS) associated with obstructive sleep apnea (OSA). Methods: A systematic review using the following terms: \"obesity hypoventilation syndrome\" AND \"treatment\" AND \"randomized\" using Cochrane Central Register of Controlled Trials, Medline and Web of Science was performed from the first data available until February 10, 2023. The inclusion criteria were: (1) original article; (2) adult OHS with concomitant OSA (apnea-hypopnea index or AHI ≥5 events/h); (3) randomized trial with PAP arm and standard care (control); (4) BMI evaluation at baseline and after the first months. We performed an individual participant data meta-analysis of randomized controlled trials.</p><p><strong>Results: </strong>Our initial search retrieved 32 articles and 3 randomized studies fulfilled study criteria and were included in the final analysis, leading to a total of 342 participants. Patients were predominantly females (62%) and had OHS associated with at least mild OSA. As compared to baseline, a decrease in BMI was observed at study endpoint but this difference was not different intergroups (-0.50 ± 1.49 and -0.50 ±1.83, in control and PAP groups respectively (p=0.939)). Weight change was not associate with PAP adherence, OSA severity or use of supplemental oxygen.</p><p><strong>Conclusions: </strong>In contrast to treatment of eucapnic OSA with PAP that is associated with weight gain, treatment of OSA+OHS patients with or without PAP is associated with weight loss. Future studies are necessary to elucidate the mechanism by which weight loss occurs.</p>","PeriodicalId":54237,"journal":{"name":"Pulmonology","volume":" ","pages":"2416816"},"PeriodicalIF":10.4,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138300594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application and internal validation of lung ultrasound score in COVID-19 setting: The ECOVITA observational study. Authors' reply. 肺部超声评分在 COVID-19 环境中的应用和内部验证：ECOVITA 观察性研究。作者回复。

IF 10.4 2区医学

Pulmonology Pub Date : 2025-12-31 Epub Date: 2024-10-24 DOI: 10.1016/j.pulmoe.2024.06.004

L Rinaldi, F Perrotta

引用次数: 0

Changed profiles of SARS-CoV-2 specific memory T cells in asthmatics with different blood eosinophil counts.

IF 10.4 2区医学

Pulmonology Pub Date : 2025-12-31 Epub Date: 2024-11-22 DOI: 10.1080/25310429.2024.2424642

Fengming Zhao, Yiting Luo, Bizhou Li, Dengxia Denise Fan, Ziyuan Xiang, Jing Li, Nanshan Zhong, Ruchong Chen

引用次数: 0

Countering antimicrobial resistance.

IF 10.4 2区医学

Pulmonology Pub Date : 2025-12-31 Epub Date: 2024-11-04 DOI: 10.1080/25310429.2024.2411807

B Adhikari, P Parajuli, S Lippmann

引用次数: 0

Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence.

IF 10.4 2区医学

Pulmonology Pub Date : 2025-12-31 Epub Date: 2025-02-05 DOI: 10.1080/25310429.2025.2457856

Irina Surovtsova, Felix J F Herth, Daria B Kokh, Philipp Morakis

{"title":"Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence.","authors":"Irina Surovtsova, Felix J F Herth, Daria B Kokh, Philipp Morakis","doi":"10.1080/25310429.2025.2457856","DOIUrl":"https://doi.org/10.1080/25310429.2025.2457856","url":null,"abstract":"<p><strong>Background: </strong>Pembrolizumab with chemotherapy (immunochemotherapy) has shown encouraging overall survival (OS) benefits in non-squamous mNSCLC, as demonstrated by the KEYNOTE-189 trial. However, randomised controlled trials may not fully capture the diversity of real-world patients. This study aims to evaluate immunochemotherapy outcomes in a real-world setting, including subgroups underrepresented in the KEYNOTE-189 trial.</p><p><strong>Methods: </strong>Patients diagnosed with non-squamous mNSCLC 2011-2022 and recorded in Cancer Registry Database of the German Federal State Baden-Württemberg (BWCR), were analysed. OS was assessed using Kaplan-Meier and multivariable Cox models, adjusted for major clinical parameters. Results were compared with KEYNOTE-189.</p><p><strong>Results: </strong>Among 2630 eligible cases, 1314 patients received chemotherapy alone and 1316 received immunochemotherapy. Median OS (mOS) was 14.1 months (95%CI: 13.1-15.4) for immunochemotherapy and 10.4 months (95%CI: 9.7-11.2) for chemotherapy alone, with an HR of 0.7 (95%CI: 0.64-0.77). A significant benefit was seen in M1c stage (HR 0.7, 95%CI: 0.63-0.79). No significant OS improvement was observed in patients with ECOG 2-3 or bone metastases.</p><p><strong>Conclusion: </strong>This real-world evidence suggests that immunochemotherapy generally improves OS in mNSCLC. Subgroup analysis showed no survival benefit for patients with ECOG >1 or bone metastasis, but a benefit for patients with M1c stage.</p>","PeriodicalId":54237,"journal":{"name":"Pulmonology","volume":"31 1","pages":"2457856"},"PeriodicalIF":10.4,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correspondence: Insights on the methodology and statistics of PAP therapy's impact on BMI.

IF 10.4 2区医学

Pulmonology Pub Date : 2025-12-31 Epub Date: 2025-02-07 DOI: 10.1080/25310429.2025.2463711

Riya Kalra, Etika Rana

引用次数: 0

Late-onset endobronchial metastasis of oncocytic cell thyroid carcinoma 晚期发生的甲状腺细胞癌支气管内转移。

IF 10.4 2区医学

Pulmonology Pub Date : 2024-11-01 DOI: 10.1016/j.pulmoe.2024.02.005

引用次数: 0

Disseminated tuberculosis mimicking pleural mesothelioma in a polycythemia vera patient treated with ruxolitinib 一名接受鲁索利替尼治疗的红细胞增多症患者发生了模仿胸膜间皮瘤的播散性结核病。

IF 10.4 2区医学

Pulmonology Pub Date : 2024-11-01 DOI: 10.1016/j.pulmoe.2024.05.003

引用次数: 0

Oral communications

IF 10.4 2区医学

Pulmonology Pub Date : 2024-11-01 DOI: 10.1016/S2531-0437(24)00120-X

引用次数: 0

Prone position for acute respiratory distress syndrome and the hazards of meta-analysis 急性呼吸窘迫综合征的俯卧位和荟萃分析的危害。

IF 10.4 2区医学

Pulmonology Pub Date : 2024-11-01 DOI: 10.1016/j.pulmoe.2022.12.005

{"title":"Prone position for acute respiratory distress syndrome and the hazards of meta-analysis","authors":"","doi":"10.1016/j.pulmoe.2022.12.005","DOIUrl":"10.1016/j.pulmoe.2022.12.005","url":null,"abstract":"<div><h3>Background</h3><div>Researchers have tried unsuccessfully for many years using randomized controlled trials to show the efficacy of prone ventilation in treating ARDS. These failed attempts were of use in designing the successful PROSEVA trial, published in 2013. However, the evidence provided by meta-analyses in support of prone ventilation for ARDS was too low to be conclusive. The present study shows that meta-analysis is indeed not the best approach for the assessment of evidence as to the efficacy of prone ventilation.</div></div><div><h3>Methods</h3><div>We performed a cumulative meta-analysis to prove that only the PROSEVA trial, due to its strong protective effect, has substantially impacted on the outcome.</div><div>We also replicated nine published meta-analyses including the PROSEVA trial. We performed leave-one-out analyses, removing one trial at a time from each meta-analysis, measuring <em>p</em> values for effect size, and also the Cochran's Q test for heterogeneity assessment. We represented these analyses in a scatter plot to identify outlier studies influencing heterogeneity or overall effect size. We used interaction tests to formally identify and evaluate differences with the PROSEVA trial.</div></div><div><h3>Results</h3><div>The positive effect of the PROSEVA trial accounted for most of the heterogeneity and for the reduction of overall effect size in the meta-analyses. The interaction tests we conducted on the nine meta-analyses formally confirmed the difference in the effectiveness of prone ventilation between the PROSEVA trial the other studies.</div></div><div><h3>Conclusions</h3><div>The clinical lack of homogeneity between the PROSEVA trial design and the other studies should have discouraged the use of meta-analysis. Statistical considerations support this hypothesis, suggesting that the PROSEVA trial is an independent source of evidence.</div></div>","PeriodicalId":54237,"journal":{"name":"Pulmonology","volume":"30 6","pages":"Pages 529-536"},"PeriodicalIF":10.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9187052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0